A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-Tissue Sarcoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 16 Oct 2014 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Cancer.
- 01 Jan 2013 Status changed from recruiting to active, no longer recruiting according to results published in the British Journal of Cancer.
- 08 May 2009 Additional trial identifiers (ACTRN12608000474358, 083144, 08/05) identified as reported by Australian New Zealand Clinical Trials Registry record.